Abstract
The purpose of the present study was to investigate whether brain reward function decreases during withdrawal from nicotine and methamphetamine, and whether decreased reward function is related to aversion during withdrawal from these drugs. For that purpose, male Sprague-Dawley rats were chronically infused subcutaneously with 9 mg/kg per day nicotine, or with 6 mg/kg per day methamphetamine using osmotic minipumps. In an intracranial self-stimulation (ICSS) paradigm, chronic infusion of nicotine and methamphetamine decreased the thresholds for lateral hypothalamic ICSS, whereas their antagonists, mecamylamine and haloperidol increased the ICSS thresholds in the rats treated with nicotine and methamphetamine, respectively. In a conditioned place aversion paradigm, mecamylamine and haloperidol produced place aversion in nicotine- and methamphetamine-infused rats, respectively. Interestingly, elevations in ICSS reward thresholds and place aversion during mecamylamine-precipitated nicotine withdrawal were almost the same in magnitude as those observed during haloperidol-precipitated methamphetamine withdrawal. The present study indicates that 1) brain reward function decreased during nicotine and methamphetamine withdrawal, and 2) a decrease in reward function may reflect the negative affective state (aversion) during withdrawal from nicotine and methamphetamine.
Keywords: Nicotine, methamphetamine, intracranial self-stimulation, conditioned place aversion, brain reward system, withdrawal, Amphetamin, ethanol
Current Neuropharmacology
Title: Decreases in Brain Reward Function Reflect Nicotine- and Methamphetamine-Withdrawal Aversion in Rats
Volume: 9 Issue: 1
Author(s): Hisatsugu Miyata, Michio Itasaka, Naofumi Kimura and Kazuhiko Nakayama
Affiliation:
Keywords: Nicotine, methamphetamine, intracranial self-stimulation, conditioned place aversion, brain reward system, withdrawal, Amphetamin, ethanol
Abstract: The purpose of the present study was to investigate whether brain reward function decreases during withdrawal from nicotine and methamphetamine, and whether decreased reward function is related to aversion during withdrawal from these drugs. For that purpose, male Sprague-Dawley rats were chronically infused subcutaneously with 9 mg/kg per day nicotine, or with 6 mg/kg per day methamphetamine using osmotic minipumps. In an intracranial self-stimulation (ICSS) paradigm, chronic infusion of nicotine and methamphetamine decreased the thresholds for lateral hypothalamic ICSS, whereas their antagonists, mecamylamine and haloperidol increased the ICSS thresholds in the rats treated with nicotine and methamphetamine, respectively. In a conditioned place aversion paradigm, mecamylamine and haloperidol produced place aversion in nicotine- and methamphetamine-infused rats, respectively. Interestingly, elevations in ICSS reward thresholds and place aversion during mecamylamine-precipitated nicotine withdrawal were almost the same in magnitude as those observed during haloperidol-precipitated methamphetamine withdrawal. The present study indicates that 1) brain reward function decreased during nicotine and methamphetamine withdrawal, and 2) a decrease in reward function may reflect the negative affective state (aversion) during withdrawal from nicotine and methamphetamine.
Export Options
About this article
Cite this article as:
Miyata Hisatsugu, Itasaka Michio, Kimura Naofumi and Nakayama Kazuhiko, Decreases in Brain Reward Function Reflect Nicotine- and Methamphetamine-Withdrawal Aversion in Rats, Current Neuropharmacology 2011; 9 (1) . https://dx.doi.org/10.2174/157015911795017218
DOI https://dx.doi.org/10.2174/157015911795017218 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Cough in Respiratory and Autoimmune Disorders
Current Respiratory Medicine Reviews Proteasome Inhibition: A Promising Strategy for Treating Cancer, but What About Neurotoxicity?
Current Medicinal Chemistry Contribution of Transcriptome to Elucidate the Biology of Plasmodium spp
Current Topics in Medicinal Chemistry Evidence-Based Management of Infertile Couples with Repeated Implantation Failure Following IVF
Current Women`s Health Reviews Neuronal Generation from Somatic Stem Cells: Current Knowledge and Perspectives on the Treatment of Acquired and Degenerative Central Nervous System Disorders
Current Gene Therapy Resveratrol as a Protective Molecule for Neuroinflammation: A Review of Mechanisms
Current Pharmaceutical Biotechnology TRP Channels: Emerging Links Between Ca2+, Kidney and Hypertension
Current Hypertension Reviews Transient Receptor Potential Channels - Emerging Novel Drug Targets for the Treatment of Pain
Current Medicinal Chemistry Prostratin: An Overview
Mini-Reviews in Medicinal Chemistry PEGylation of Proteins and Liposomes: a Powerful and Flexible Strategy to Improve the Drug Delivery
Current Drug Metabolism Relevance of Neuropeptide Y (NPY) in Psychiatry
Current Topics in Medicinal Chemistry Cellular Reservoirs of HIV-1 and their Role in Viral Persistence
Current HIV Research Functional Genomics of the Oxidative Stress Pathway
Current Hypertension Reviews MicroRNAs Determining Inflammation as Novel Biomarkers and Potential Therapeutic Targets
Current Medicinal Chemistry The Potential and Limitations of p38MAPK as a Drug Target for the Treatment of Hematological Malignancies
Current Drug Targets Impact of Ultrasound Contrast Agents in Echocardiographic Assessment of Ischemic Heart Disease
Recent Patents on Cardiovascular Drug Discovery Withdrawal Notice: Therapeutic Options for Treatment of COVID-19: A Review from Repurposed Drugs to New Drug Targets
Current Drug Targets PDE5 Inhibitors in Non-Urological Conditions
Current Pharmaceutical Design Pathogenesis of the Podocytopathy and Proteinuria in Diabetic Glomerulopathy
Current Diabetes Reviews The Na+/H+ Exchanger: A Target for Cardiac Therapeutic Intervention
Current Drug Targets - Cardiovascular & Hematological Disorders